DK1218009T3 - Quetiapingranulater - Google Patents

Quetiapingranulater

Info

Publication number
DK1218009T3
DK1218009T3 DK00960855T DK00960855T DK1218009T3 DK 1218009 T3 DK1218009 T3 DK 1218009T3 DK 00960855 T DK00960855 T DK 00960855T DK 00960855 T DK00960855 T DK 00960855T DK 1218009 T3 DK1218009 T3 DK 1218009T3
Authority
DK
Denmark
Prior art keywords
quetiaping
granules
quetiaping granules
Prior art date
Application number
DK00960855T
Other languages
English (en)
Inventor
Daniel Boyd Brown
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1218009(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1218009T3 publication Critical patent/DK1218009T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
DK00960855T 1999-09-21 2000-09-18 Quetiapingranulater DK1218009T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9922271.3A GB9922271D0 (en) 1999-09-21 1999-09-21 Formulation
EP00960855A EP1218009B1 (en) 1999-09-21 2000-09-18 Quetiapine granules
PCT/GB2000/003598 WO2001021179A1 (en) 1999-09-21 2000-09-18 Quetiapine granules

Publications (1)

Publication Number Publication Date
DK1218009T3 true DK1218009T3 (da) 2005-05-09

Family

ID=10861288

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00960855T DK1218009T3 (da) 1999-09-21 2000-09-18 Quetiapingranulater

Country Status (37)

Country Link
US (3) US6599897B1 (da)
EP (1) EP1218009B1 (da)
JP (1) JP2003509461A (da)
KR (1) KR100748823B1 (da)
CN (3) CN1899288A (da)
AR (1) AR032596A1 (da)
AT (1) ATE288272T1 (da)
AU (1) AU776292B2 (da)
BG (1) BG65469B1 (da)
BR (1) BR0014107A (da)
CA (1) CA2383131A1 (da)
CO (1) CO5180585A1 (da)
CZ (1) CZ301585B6 (da)
DE (1) DE60017923T2 (da)
DK (1) DK1218009T3 (da)
EE (1) EE200200150A (da)
EG (1) EG24226A (da)
ES (1) ES2235941T3 (da)
GB (2) GB9922271D0 (da)
HK (1) HK1047706B (da)
HU (1) HUP0203531A3 (da)
IL (2) IL148440A0 (da)
IS (1) IS2139B (da)
MX (1) MXPA02002627A (da)
MY (1) MY130208A (da)
NO (1) NO320908B1 (da)
NZ (1) NZ517549A (da)
PL (1) PL198824B1 (da)
PT (1) PT1218009E (da)
RU (1) RU2256453C2 (da)
SI (1) SI1218009T1 (da)
SK (1) SK286884B6 (da)
TR (1) TR200200716T2 (da)
TW (1) TWI226832B (da)
UA (1) UA73529C2 (da)
WO (1) WO2001021179A1 (da)
ZA (1) ZA200201709B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
WO2003039516A1 (en) * 2001-11-07 2003-05-15 Fujisawa Pharmaceuticla Co., Ltd. Method for improving dissolution of poorly dispersible medicaments
JP4514473B2 (ja) * 2004-02-23 2010-07-28 富士通株式会社 コンピュータシステム、中央装置及びプログラム実行方法
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
WO2006117700A2 (en) * 2005-04-21 2006-11-09 Medichem, S.A. Process for preparing quetiapine and quetiapine fumarate
EP1976487A2 (en) 2006-01-25 2008-10-08 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
EP2021325A2 (en) * 2006-05-09 2009-02-11 AstraZeneca AB Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
WO2008012346A1 (en) * 2006-07-28 2008-01-31 Farmaprojects, S. A. Extended release pharmaceutical formulation of metoprolol and process for its preparation
TW200829244A (en) * 2006-09-15 2008-07-16 Astrazeneca Ab Therapeutic combinations 482
US8623861B2 (en) * 2006-11-03 2014-01-07 Xin-Min Li Method of treating demyelination diseases
EP2112923A1 (en) * 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
EP1958617B1 (en) 2007-02-14 2010-09-08 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing quetiapine fumarate
MX345970B (es) * 2008-02-27 2017-02-28 Intercontinental Great Brands Llc Confiteria de regiones multiples.
DE202009018024U1 (de) 2008-08-01 2010-12-09 Krka Tovarna Zdravil, D.D., Novo Mesto Quetiapin-Zusammensetzung
DE102008046650A1 (de) 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
RS58335B1 (sr) 2010-03-11 2019-03-29 Kempharm Inc Konjugati kvetiapina sa masnom kiselinom, proces za njihovo dobijanje i njihova primena
BR112012029326A2 (pt) 2010-05-20 2017-08-08 Astrazeneca Ab processo para a preparação de animais olefínicas substituídas por arila
DE102010033527A1 (de) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapin-Tabletten
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
EP4142735A4 (en) * 2020-04-29 2024-06-19 Stepan Company SOLID COMPOSITIONS CONTAINING AMINE, PROTONATED AMINE OR QUATERNARY AMMONIUM COMPOUNDS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
ES2054259T3 (es) * 1989-08-31 1994-08-01 Takeda Chemical Industries Ltd Composicion de vitamina b12.
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
JPH06100602A (ja) * 1992-09-18 1994-04-12 Asahi Chem Ind Co Ltd 経口固形製剤およびその製造方法
US5397576A (en) * 1992-09-23 1995-03-14 Hoffmann-La Roche Inc. Spray triturated micronutrient compositions
EP0667866B1 (en) * 1992-11-09 1998-03-11 Knoll AG 1,4-benzothiazepines useful as neurological agents
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
JP2001501207A (ja) * 1996-09-24 2001-01-30 イーライ・リリー・アンド・カンパニー コーティングされた粒子製剤
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation

Also Published As

Publication number Publication date
EP1218009B1 (en) 2005-02-02
BG65469B1 (bg) 2008-09-30
US20060159768A1 (en) 2006-07-20
KR100748823B1 (ko) 2007-08-13
CN1899288A (zh) 2007-01-24
CN1331472C (zh) 2007-08-15
HK1047706A1 (en) 2003-03-07
EP1218009A1 (en) 2002-07-03
UA73529C2 (uk) 2005-08-15
BG106509A (en) 2002-12-29
DE60017923T2 (de) 2006-01-12
CA2383131A1 (en) 2001-03-29
US20040228914A1 (en) 2004-11-18
HUP0203531A3 (en) 2004-12-28
TR200200716T2 (tr) 2002-06-21
ATE288272T1 (de) 2005-02-15
GB0021406D0 (en) 2000-10-18
HUP0203531A2 (hu) 2003-02-28
KR20020033186A (ko) 2002-05-04
ES2235941T3 (es) 2005-07-16
RU2256453C2 (ru) 2005-07-20
IL148440A (en) 2007-07-04
CN1188130C (zh) 2005-02-09
IL148440A0 (en) 2002-09-12
EE200200150A (et) 2003-04-15
MXPA02002627A (es) 2002-07-30
ZA200201709B (en) 2003-05-28
PT1218009E (pt) 2005-05-31
PL357369A1 (en) 2004-07-26
US6599897B1 (en) 2003-07-29
NO320908B1 (no) 2006-02-13
CO5180585A1 (es) 2002-07-30
TWI226832B (en) 2005-01-21
SI1218009T1 (en) 2005-06-30
MY130208A (en) 2007-06-29
CN1374867A (zh) 2002-10-16
EG24226A (en) 2008-11-10
AU7302300A (en) 2001-04-24
CN1626094A (zh) 2005-06-15
GB9922271D0 (en) 1999-11-17
PL198824B1 (pl) 2008-07-31
BR0014107A (pt) 2002-08-20
US7022692B2 (en) 2006-04-04
SK3722002A3 (en) 2002-07-02
IS6308A (is) 2002-03-19
CZ2002974A3 (cs) 2002-06-12
HK1047706B (en) 2005-06-10
JP2003509461A (ja) 2003-03-11
DE60017923D1 (de) 2005-03-10
NO20021394D0 (no) 2002-03-20
CZ301585B6 (cs) 2010-04-21
NZ517549A (en) 2003-10-31
AR032596A1 (es) 2003-11-19
IS2139B (is) 2006-08-15
NO20021394L (no) 2002-03-20
WO2001021179A1 (en) 2001-03-29
SK286884B6 (sk) 2009-07-06
AU776292B2 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
DE60005976D1 (de) Speicherkkarte
DE50010505D1 (de) Gurtaufrollersystem
DE60039942D1 (de) Selbstbräununsschaum
DE122007000064I2 (de) Erythropoietinkonjugate
DE19983871T1 (de) Fönvorrichtung
DE10084676T1 (de) Einmallanzettvorrichtung
DE60004192D1 (de) Kompositverschlusskappe
DE50002834D1 (de) Handstempel
NO20020487D0 (no) 2-Pyrazolin-5-oner
IS2139B (is) Kvetíapínagnir
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
NO996149D0 (no) Skjaerboelgegenerator
DE50015451D1 (de) Spülwannensystem
DE50008613D1 (de) Sicherungsring
DE50012482D1 (de) Tibiamarknagel
DE50000805D1 (de) Aufsitzspanner
DE50006899D1 (de) Antistatikum
DE10085008T1 (de) Oberflächenbehandlungsdüse
DE50006013D1 (de) Anschlagpuffer
DE50003259D1 (de) Textilie
DE50008429D1 (de) Kraftstofffraktioniereinrichtung
DE50001640D1 (de) Nahfeldoptische untersuchungsvorrichtung
DE50006759D1 (de) Piperidinalkohole
DE50009208D1 (de) Hydroxyphenylvinylthiazole
ATE440824T1 (de) Nitro-sulfobenzamide